LPTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LPTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Leap Therapeutics's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Leap Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.73.
The historical data trend for Leap Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leap Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Accounts Receivable | Get a 7-Day Free Trial | - | - | - | - | - |
Leap Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Accounts Receivable | Get a 7-Day Free Trial | - | - | - | - | - |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Leap Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Leap Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Leap Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (54.921 | + | 0.75 * 0 | + | 0.5 * 0 | - | 10.591 |
- | 0 | - | 0) | / | 25.6035 | ||
= | 1.73 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of Leap Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Jason Baum | officer: Chief Scientific Officer | LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141 |
Patricia A. Martin | director | 316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260 |
Christian M Richard | director | 100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110 |
Richard Schilsky | director | LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141 |
Beigene, Ltd. | 10 percent owner | C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Christine Granfield | officer: VP, Head of Reg Affairs/Qual | C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
John Mark O'mahony | officer: Chief Manufacturing Officer | C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
Cynthia Sirard | officer: Chief Medical Officer | C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Christopher Mirabelli | director, 10 percent owner, officer: CEO,Pres,Chairman of the Board | 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142 |
Augustine Lawlor | 10 percent owner, officer: Chief Operating Officer | 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142 |
Douglas E Onsi | 10 percent owner, officer: CFO,Gen Counsel,Treas, Sec. | C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Healthcare Ventures Ix, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire • 01-02-2024
By Business Wire Business Wire • 01-24-2023
By PRNewswire PRNewswire • 01-11-2023
By PRNewswire PRNewswire • 08-12-2022
By PRNewswire PRNewswire • 05-25-2023
By PRNewswire PRNewswire • 04-26-2023
By PRNewswire PRNewswire • 06-15-2022
By PRNewswire PRNewswire • 06-27-2022
By PRNewswire PRNewswire • 07-07-2022
By PRNewswire PRNewswire • 01-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.